Brentuximab vedotin with AVD shows safety, in the absence of strong CYP3A4 inhibitors, in newly diagnosed HIV-associated Hodgkin lymphoma.
about
Brentuximab vedotin with AVD shows safety, in the absence of strong CYP3A4 inhibitors, in newly diagnosed HIV-associated Hodgkin lymphoma.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Brentuximab vedotin with AVD s ...... V-associated Hodgkin lymphoma.
@en
Brentuximab vedotin with AVD s ...... V-associated Hodgkin lymphoma.
@nl
type
label
Brentuximab vedotin with AVD s ...... V-associated Hodgkin lymphoma.
@en
Brentuximab vedotin with AVD s ...... V-associated Hodgkin lymphoma.
@nl
prefLabel
Brentuximab vedotin with AVD s ...... V-associated Hodgkin lymphoma.
@en
Brentuximab vedotin with AVD s ...... V-associated Hodgkin lymphoma.
@nl
P2093
P2860
P1433
P1476
Brentuximab vedotin with AVD s ...... V-associated Hodgkin lymphoma.
@en
P2093
AIDS Malignancy Consortium (AMC)
Ariela Noy
David H Henry
Elad Sharon
Juan C Ramos
Lee Ratner
Michelle A Rudek
Page C Moore
Paul G Rubinstein
P2860
P356
10.1097/QAD.0000000000001729
P407
P577
2017-12-26T00:00:00Z